Health Canada Approves Groundbreaking Treatment for Alzheimer's Disease
In a significant advancement for Alzheimer’s disease treatment, Health Canada has issued a Notice of Compliance for Leqembi® (lecanemab). This approval allows for the use of Leqembi in adult patients suffering from mild cognitive impairment or mild dementia related to Alzheimer’s disease. Specifically, this is for patients who are either non-carriers or heterozygotes of the apolipoprotein E ?4 gene and have been confirmed to possess amyloid pathology.
Leqembi represents an innovative approach as it selectively binds to both soluble A? aggregates (protofibrils) and insoluble A? aggregates (fibrils), which form A? plaques in the brain. This dual action not only helps to reduce these aggregates but also marks a groundbreaking step as it is the first treatment for Alzheimer’s that targets an underlying cause of the disease. Moreover, it has been shown to reduce the rate of disease progression and slow cognitive decline in adults.
This treatment has already received approval in 51 different countries including the United States, the United Kingdom, Europe, and several others. More than nine countries are currently considering its market application. The approval stems from comprehensive research, particularly the large-scale Phase 3 Clarity AD study, where Leqembi successfully met its primary objectives alongside all critical secondary endpoints with statistically significant results.
The Growing Need for Alzheimer’s Treatments
Alzheimer’s disease is a major global health issue, accounting for 60 to 80 percent of all dementia cases. Recent estimates suggest that in the near future, the number of dementia patients in Canada could soar to over 1 million by 2030 and reach upwards of 1.7 million by 2050. This highlights the urgent need for effective treatments as more individuals and their families face the challenges associated with this condition.
Furthermore, the annual caregiving provided by family and friends for those battling dementia is comparable to a workforce of approximately 290,000 full-time positions, projected to increase dramatically in coming years. Leqembi provides hope not only for affected individuals but also for their families and caregivers who shoulder tremendous responsibility.
Collaboration Between BioArctic and Eisai
Leqembi is the product of a robust partnership between BioArctic and Eisai. The development of this antibody stems from the pioneering work of Professor Lars Lannfelt, who discovered the Arctic mutation linked to Alzheimer’s disease. Eisai has taken the lead on clinical development, market applications, and the commercialization of Leqembi globally, while BioArctic maintains rights for commercialization within the Nordic region.
This partnership began in 2005 and has led to multiple agreements that enhance the collaboration between the two companies. Eisai’s responsibilities include capturing clinical assessment data from real-world practice to further substantiate Leqembi’s clinical benefits.
A Look at the Future
As clinical trials and studies continue, additional treatments such as the ongoing AHEAD 3-45 study, which involves participants with preclinical Alzheimer’s, show promise in refining therapeutic strategies. With a focus on preventing progression before cognitive symptoms arise, these studies represent a paradigm shift in Alzheimer’s disease research and treatment.
Moreover, BioArctic is expanding its research portfolio to include treatments for related neurodegenerative diseases such as Parkinson’s disease and ALS. The unique BrainTransporter™ technology developed by BioArctic aims to enhance the efficacy of treatments by improving the transport of antibodies across the blood-brain barrier.
About BioArctic AB
BioArctic AB (publ) is a Swedish biopharmaceutical company committed to discovering and developing innovative solutions for neurodegenerative diseases. It has pioneered Leqembi® (lecanemab), becoming the world’s first drug to slow the progression of early Alzheimer’s disease. Beyond lecanemab, BioArctic’s future endeavors include treatments for a range of conditions, promising advancements in medical science and healthcare.
Frequently Asked Questions
What is Leqembi used for?
Leqembi is used for treating mild cognitive impairment or mild dementia in Alzheimer's disease patients.
Which countries have approved Leqembi?
Leqembi has been approved in 51 countries, including the USA, Japan, and multiple European nations.
What underlies the efficacy of Leqembi?
Leqembi works by targeting soluble and insoluble A? aggregates, aiming to reduce both amyloid plaques and protofibrils in the brain.
How has Leqembi been tested?
Leqembi was validated through the Phase 3 Clarity AD study, which showcased its effectiveness in meeting key clinical endpoints.
Who developed Leqembi?
Leqembi is developed through a collaboration between BioArctic AB and Eisai, leveraging groundbreaking Alzheimer’s research.
